The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Issue 9 (28th March 2018)

• Record Type: Journal Article
• Authors: Hirschfield, Gideon M; Dyson, Jessica K; Alexander, Graeme J M; Chapman, Michael H; Collier, Jane; Hübscher, Stefan; Patanwala, Imran; Pereira, Stephen P; Thain, Collette; Thorburn, Douglas; Tiniakos, Dina; Walmsley, Martine; Webster, George; Jones, David E J
• Is Part Of: Gut. Volume 67:Issue 9(2018)
• Page Start: 1568
• Page End: 1594
• Publication Date: 2018-03-28
• Subjects: autoimmune liver disease -- care pathway -- guidelines -- ursodeoxycholic acid -- obeticholic acid; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2017-315259
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation. PBC is most prevalent in women and those over the age of 50, but a spectrum of disease is recognised in adult patients globally; male sex, younger age at onset (<45) and advanced disease at presentation are baseline predictors of poorer outcome. As the disease is increasingly diagnosed through the combination of cholestatic serum liver tests and the presence of antimitochondrial antibodies, most presenting patients are not cirrhotic and the term cholangitis is more accurate. Disease course is frequently accompanied by symptoms that can be burdensome for patients, and management of patients with PBC must address, in a life-long manner, both disease progression and symptom burden. Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients and risk stratification based on baseline and on-treatment factors, including in particular the response to treatment. Those intolerant of treatment with UDCA or those with high-risk disease as evidenced by UDCA treatment failure (frequently reflected in trial and clinical practice as an alkaline phosphatase >1.67 × upper limit of normal and/or elevated bilirubin) should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended agent. Follow-up of patients is life-long and must address treatment of the disease and management of associated symptoms.